How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?

How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?

How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research Rheumatology Division Professor of Medicine University of Massachusetts Medical School Worcester, MA